STOCKS TELEGRAPH

Author: Shimrez Hyder

  • Kohl’s Corp. (KSS) Stock on the Rise Following Disclosure of Stellar Financial Reports for Q2 2021

    Kohl’s Corp. (KSS) stock prices were up by 6.46% shortly after market trading commenced on August 19th, 2021. This brought the price per share up to USD$55.20 early on in the trading day.

    Net Sales and EPS

    Net sales for the second quarter of 2021 were up by 31.4% as compared to the prior-year quarter. KSS stock also reported record second-quarter earnings per share in the amount of USD$2.48 per diluted share. Both net sales and EPS exceeded expectations, resulting in the company raising its full-year financial outlook for 2021. Guidance for diluted earnings per share has been bumped up to range from USD$5.80 to USD$6.10. The quarter ended with the company reporting a strong liquidity position with USD$2.6 billion in cash. The second quarter also saw the company repurchase USD$255 million of shares. The company forecasts repurchasing from USD$500 million to USD$700 million of shares over the rest of fiscal 2021.

    KSS Stock Exceeds Expectations

    The company performance over the second quarter of fiscal 2021 consolidated KSS stock as a leading option for active and casual lifestyles. The delivery of record EPS and the exceeding of forecasts, the company continues to facilitate its strategic progress. The upcoming quarters are rife with opportunity, with the company on the cusp of launching several transformational partnerships. This is expected to drive sustainable growth for the upcoming years.

    Net Sales Reports

    Net sales are now expected in the low-twenties percentage range, up from a previous forecast of mid-to-high teens percentage range increase. The second quarter of fiscal 2021 saw KSS stock report operating margin expected in the range of 7.4% to 7.6%. This is up from the range of 5.7% to 6.1% that was previously forecasted for the full fiscal year 2021.

    KSS Stock’s Dividend

    August 10th, 2021 saw KSS stock report its Board of Directors having approved and declared a quarterly cash dividend. The dividends on the company’s common stock will be value at USD$0.25 per share to shareholders of record as of the close of market trading on September 8th, 2021. The dividend will be payable on September 22nd, 2021.

    Future Outlook for KSS Stock

    The company reported a stellar second quarter of fiscal 2021, with KSS stock having raised full year guidance accordingly. The company is keen to execute its business plan in order to usher in organic growth over the long term. Investors are hopeful that management will be able to drive significant and sustained increases in shareholder value.

  • Macy’s Inc. (M) Stock Surges Following Disclosure of Promising Financial Reports for Q2 2021

    Macy’s Inc. (M) stock prices surged by 13.44% just before market trading commenced on August 19th, 2021. This brought the price per share down to USD$20.51 early on in the trading day.

    Solid Liquidity Position

    The second quarter of fiscal 2021 ended with M stock reported roughly USD$2.1 billion in cash. The solid liquidity position allows the company to execute on its two priorities. These priorities are the driving of profitable growth with appropriate investments while de-levering the balance sheet. Their liquidity position will also facilitate the reinstatement of the company’s regular quarterly dividend. Valued at USD$0.15 per share, this will result in an annual return of cash to shareholders in the amount of nearly USD$200 million.

    M Stock’s Share Repurchase Program

    M stock also announced during the second quarter of fiscal 2021 that its board of directors had authorized a share repurchase program. The program will see the company purchase up to a total of USD$500 million worth of shares over time. The company also announced having voluntarily repaid USD$1.3 billion in Senior Secured Notes on August 17th, 2021. As a result of this move, the company now forecasts exceeding its target leverage ratio. The expected ratio will be no more than 2.5x by the end of fiscal 2021, as per M stock’s projections.

    Adapting to the Pandemic

    The ongoing global pandemic continues to cause uncertainty, but, despite this, M stock managed to increase the traction of its Polaris strategy. The strong performance shown by the second quarter of 2021 inspires confidence that translated into a material increase in full-year guidance for 2021. The company has also adjusted its long-term Adjusted EBITDA margin target, expected low double digits at the start of the next fiscal year.

    M Stock’s EPS Reports

    Earnings per share came out to USD$1.08 per diluted common share and Adjusted diluted earnings per share in the amount of USD$1.29. Both reports surpass previously announced guidance for the quarter. The second quarter of fiscal 2020 saw M stock report diluted earnings per share and Adjusted diluted EPS in the amount of USD$0.28.

    Future Outlook for M Stock

    The company reported a strong quarter which has set the stage for a continued trajectory of success. M stock is keen to leverage the resources at its disposal to drive organic growth over the long term. Current and potential investors are hopeful that this will translate into consistent increases in shareholder value over time.

  • Baozun Inc. (BZUN) Stock Trends Lower Following Announcement of Q2 2021 Financial Reports

    Baozun Inc. (BZUN) stock prices were down by 7.12% around the market opening on August 19th, 2021. This brought the price per share down to USD$19.64 early on in the trading day.

    Product Sales Revenue

    The second quarter of fiscal 2021 saw BZUN stock report USD$150.6 million in product sales revenue. This represents a 4.8% increase from numbers reported for the prior-year quarter. The year-over-year difference is largely attributable to the acquisition of new brand partners. Further consolidating the yearly difference was the increased popularity of the company’s brand partners’ products. The difference was partially offset, however, by slower growth in personal-care products in the appliances category.

    BZUN Stock’s Collaboration with eFashion China

    June 28th 2021 saw BZUN stock announce the signing of a definitive agreement with eFashion China. As per the agreement, the company would acquire a 100% equity interest in the leading provider of e-commerce solutions for fashion brands across China. The all-cash transaction positions the company to effectively penetrate the apparel segment of the market, thereby consolidating its market leadership. The transaction is expected to close around September of 2021, after which eFashion China will serve as a sub-brand of BZUN stock.

    BZUN Stock’s Partnership with Cainiao

    July 22nd, 2021 saw BZUN stock announce the signing of a letter of intent with Cainiao in regard to its equity investment in Baotong. Baotong is the company’s warehousing and fulfillment solution subsidiary. Baozun, Baotong, and Cainiao also entered into a Letter of Intent of Business Cooperation Agreement. This agreement will see the partners seek to further explore and develop brand e-commernce opportunities.

    Scope of Partnerships

    The three partnering companies plan to cooperate and coordinate to develop competitive solutions in customized, high-value, and digitalized logistics services. Baotong could potentially also facilitate the provision of operational and technological management and consulting services to Cainiao’s overall consumer base. BZUN stock and Baotong hope to leverage Cainiao’s national logistics expertise and technology. By doing so, they hope to greatly improve their cost structure, while actively enriching their service offerings portfolio.

    Future Outlook for BZUN Stock

    The company reported a strong second quarter of fiscal 2021, with BZUN stock poised to capitalize on the opportunities afforded by its expanding network of partners. The company is keen to leverage the resources at its disposal to continue the trajectory of success. Investors are hopeful that this will translate into significant and sustained increases in shareholder value.

  • Tremor International Ltd. (TRMR) Stock on the Rise Following Disclosure of Financial Reports for Q2 2021

    Tremor International Ltd. (TRMR) stock prices were up by 2.69% as of the market closing on August 18th, 2021. This brought the price per share up to USD$19.88 early on in the trading day. Subsequent premarket fluctuations have seen the stock rise by 4.38%, bringing it up to USD$20.75.

    TRMR Stock’s Capital Generation

    June 22nd 2021 saw the company announced raising USD$128.6 million in gross proceeds. The funds were generated from the sale of the company’s American Depositary Shares (ADSs) on the NASDAQ Global Market. TRMR stock also generated an additional USD$19.3 million through the exercising of an over-allotment option by the underwriters of the offering. The ADSs began trading on the NASDAQ Global Market under the ticker symbol TRMR.

    Solid Liquidity Position

    The NASDAQ listing is expected to provide TRMR stock with greater visibility among potential and current consumers. The company plans to allocate the net proceeds generated from the offering towards working capital, general corporate purposes. The funds are also expected to be allocated towards driving incremental growth, including potential acquisitions in the future. As of June 30th 2021, the company reported cash and cash equivalents in the amount of USD$275.5 million, with no debt outstanding.

    Omnichannel Solution

    TRMR stock reported expanding its Omnichannel solution, which serves to empower advertisers to complement their video campaigns with premium listening environments through programmatic audio. The solution allows the ability to run standard or tag-based audio campaigns with supply partners such as AdsWizz, Pandora, and Spotify. The solution also facilitates the ability to target smart speakers like Amazon Echo and Google Home through connected device targeting.

    TRMR Stock’s Recent Developments

    The second quarter of fiscal 2021 saw TRMR stock launch new partnerships with Tegna, Rakuten Viki, and A&E. the quarter also saw the company announce the completion of support for LiveRamp’s IdentityLink solution and Unified ID 2.0 in the Exchange. This serves to facilitate industry initiatives to support a cookie-less world. The company launched in-house TV retargeting over the quarter, as well as a measurement solution. This solution provides brand advertisers the ability to reach and engage TV viewing audiences at scale with Data-Driven Video Creative (DDC).

    Future Outlook for TRMR Stock

    The company reported a strong quarter, with TRMR stock keen to maintain the momentum of its trajectory of success. The company is executing their business strategy by leveraging the resources at their disposal. Investors are hopeful that this will results in consistent gains in shareholder value over the long term.

  • RealNetworks Inc. (RNWK) Stock on the Rise Following Announcement of Collaboration with NTT Doconomo

    RealNetworks Inc. (RNWK) stock prices were up by 9.43% as of the market closing on August 18th 2021. This brought the price per share up to USD$1.74 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 7.47%, bringing it up to USD$1.87.

    RNWK Stock’s Collaboration

    August 18th 2021 saw the premier facial recognition platform for live video sign a reseller agreement with NTT Docomo. The collaboration with Japan’s largest mobile carrier will facilitate the offering of SAFR’s world class AI-based facial recognition software. This is a continuation of the two companies’ relationship, having previously collaborated to implement access-control and security solutions for a large facility, a hospital, and a robot. The combination of NTT Docomo’s 5G infrastructure and RNWK stock’s facial recognition will see the partnership accelerate further enterprise security and access control deployments as per the new agreement.

    Individual Strengths

    RNWK stock’s efficient design facilitates high speed results enabling more simultaneous face detections over 5G networks with low latency. The company’s small footprint also allows for the installation of cheaper edge compute platforms that are used for a myriad of solutions. These solutions include, but are not limited to, access control, watch-list based surveillance, business intelligence, and demographic analysis.

    Scope of RNWK’s Collaboration

    Age, gender, and sentiment analysis will allow for the provision of real-time metrics to organizations with storing any personal identifiable information. The solution has the potential to be easily deployed as part of a multi-factor authentication solution. Online payment processing and similar use cases will also be facilitated. RNWK stock’s customers will be provided with additional options that will offer accurate, high-speed AI facial recognition capabilities. In conjunction with their existing products, SAFR hopes to solve complex challenges for access control and surveillance while providing actionable business intelligence.

    Ahead of the Competition

    RNWK stock’s computer vision code is a frontrunner in small and efficient offerings in the facial recognition marketplace. This makes it easy to deploy in edge devices. The latest version 3.5 supports liveness detection, which serves to prevent fraudulent access via photos and videos that might allow access on less secure systems.

    Future Outlook for RNWK Stock

    The company reported a strong quarter, with the recent collaboration consolidating its trajectory of success. RNWK stock is keen to effectively leverage the resources at its disposal. Shareholders are hopeful for significant and sustained increases in shareholder value.

  • JOYY Inc. (YY) Stock Exhibits Minor Volatility Following Disclosure of Financial Reports for Q2 2021

    JOYY Inc. (YY) stock prices were up by 1.28% as of the market closing on August 18th, 2021. This brought the price per share up to USD$41.02 at the end of the trading day. Subsequent premarket fluctuations have seen the stock dip by 6.51%, bringing it down to USD$38.35.

    YY Stock’s Revenue Breakdown

    Net revenues for the quarter were up by 39.7% for the second quarter of 2021, up to USD$661.7 million. This is comparable to the USD$473.5 million in the prior-year quarter. The year-over-year difference was largely attributable to the growth of live streaming revenues from BIGO. Live streaming revenues were up by 39.7%, coming in at USD$629.6 million in Q2 2021. This is comparable to the USD$450.7 million in the second quarter of fiscal 2020. The year-over-year difference was largely attributable to BIGO’s ongoing expansion of paying users and enhanced monetization capabilities.

    Costs of Revenue

    YY stock reported a 32.2% year-over-year increase in costs of revenue in the second quarter of fiscal 2021. The 2021 quarter came in at USD$458.3 million, as compared to the USD$346.7 million in the prior-year quarter. Revenue-sharing fees and content costs were up to USD$289.1 million for the second quarter of 2021, up from the USD$198.2 million in the 2020 quarter. This year-over-year difference was largely driven by increases in live streaming revenues generated by the company.

    YY Stock’s Operating Loss

    The second quarter of fiscal 2021 saw YY stock report an operating loss in the amount of USD$101.1 million This is comparable to the USD$119.9 million reported in the prior-year quarter. Operating loss margin for the 2021 quarter came in at 15.3%, down from the 25.3% reported in the 2020 quarter. The year-over-year difference was largely attributable to BIGO turning a profit in Q2 2021.

    Net Loss Reports

    Net loss from continuing operations attributable to shareholders came in at USD$109.3 million for Q2 2021. This is comparable to the USD$28.5 million reported in the prior-year quarter. Net loss margin was reported at 16.5% for the 2021 quarter, with the 2020 quarter reporting a net loss margin of 6%.

    Future Outlook for YY Stock

    The company reported a strong quarter, with YY stock executing its business strategy to facilitate a continued trajectory of success. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.

  • Coherus Biosciences Inc. (CHRS) Stock Surges Following Positive Interim Results of CHOICE-01 Study

    Coherus Biosciences Inc. (CHRS) stock prices were down by 3.61% as of the market closing on August 18th, 2021. This brought the price per share down to USD$14.14 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 19.66%, bringing it up to USD$16.92.

    CHRS-01 Stock’s CHOICE-01 Trial

    August 18th, 2021 saw CHRS stock announce positive interim results from the pivotal study CHOICE-01. The announcement was made in collaboration with Junshi Biosciences. The randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab. The treatment was administered with chemotherapy as a first-line treatment of advanced squamous or non-squamou non-small cell lung cancer (NSCLC). The interim analysis met the primary endpoint, which demonstrated a statistically significant and clinically meaningful improvement in progression-free surivive. PFS was measure per RECIST v1.1, as compared to chemotherapy alone.

    Upcoming Presentation

    The results of the study will be summarized on September 13th in an oral presentation by Professor Jie Wang, MD, Ph.D. The exhibition will take place during the Mini Oral Session at the 2021 World Conference on Lung Cancer (WCLC). The event is hosted by the International Association for the Study of Lung Cancer (IASLC), with the abstract being available on the WCLC website.

    About the Study

    Patients enrolled in the CHOICE-01 study exhibited advanced non-small cell lung cancer. The patients demonstrated the clinical benefit of toripalimab in another first-line setting. This builds on the evidence of efficacy in first-line studies in nasopharyngeal carcinoma and esophageal squamous cell carcinoma. The clinical profile of the treatment has been established as excellent across various tumor types. The company is setting the stage to pursue registration for toripalimab for a range of indications in China, the U.S. and other markets.

    CHRS Stock’s Resounding Success

    The efficacy and safety data from the study were compelling, demonstrating the treatment’s potential to deliver the significant benefits. The PD-1 class of checkpoint inhibitor drugs has been consolidated in the treatment of patients with non-small cell lung cancer. As data is gathered over the course of the pivotal studies, the treatment is showing itself to be an excellent checkpoint inhibitor. The company is anticipating results from additional oncological Phase 3 studies.

    Future Outlook for CHRS Stock

    The company reported highly promising developments in its CHOICE-01 study, with CHRS stock excited to further progress their flagship treatment. The company is keen to accelerate the commercialization and proliferation of their treatment. Investors are hopeful for significant and sustained increases in shareholder value.

  • Sema4 Holdings Corp. (SMFR) Stock Plummets Following Disclosure of Financial Report for Q2 2021

    Sema4 Holdings Corp. (SMFR) stock prices were down by 14.61% shortly after market trading commenced on August 17th, 2021. This brought the price per share down to USD$9.70 early on in the trading day.

    SMFR Stock’s Revenue Breakdown

    The second quarter of fiscal 2021 saw SMFR stock report total revenues in the amount of USD$46.9 million. This is comparable to the USD$30.1 million reported for the second quarter of 2020. Revenue growth was largely attributable to an increase in the volume of Women’s Health and Oncology solutions. Further year-over-year growth was facilitated by growth in collaboration service activities. This growth stems from the execution of three new third-party contracts.

    Costs of Services

    SMFR stock reported costs of services in the amount of USD$49.6 million in the second quarter of 2021, up from the USD$36 million reported in the prior-year quarter. This year-over-year difference was largely driven by increased volumes in the company’s non-Covid business. An expanded footprint in its Stamford lab and an expanded headcount also contributed to the year-over-year difference. Further consolidating the increase were temporary labor costs related to the global pandemic, and higher logistical and supply costs.

    SMFR Stock’s Operating Expense

    Operating expenses for the second quarter of fiscal 2021 came in at USD$41.9 million. This is comparable to the USD$28.3 million reported for the second quarter of fiscal 2020. The year-over-year difference was largely attributable to higher personnel-related costs. Consolidating the yearly difference were professional services related to the business combination.

    Strong Liquidity Position

    Net loss for the second quarter of 2021 came in at USD$45.4 million, as compared to the net loss of USD$32.1 million reported for the prior-year quarter. The 2021 quarter, ended June 30th, 2021, saw SMFR stock report a strong liquidity position. As of the end of the quarter, the company reported cash and cash equivalents in the amount of USD$26.5 million. This is excluding the USD$510 million net cash proceeds generated from the consummation of their business combination in July of 2021.

    Future Outlook for SMFR

    SMFR stock reported a strong quarter, rife with developments that will open up new opportunities. The company is keen to meet these opportunities head on in a bid to continue its trajectory of success. Current and potential investors are hopeful that management will facilitate consistent increases in shareholder value over the long term.

  • Cyclo Therapeutics Inc. (CYTH) Stock on the Rise Following Disclosure of Financial Reports for Q2 2021

    Cyclo Therapeutics Inc. (CYTH) stock prices were up by 5.97% shortly before the start of market trading on August 17th 2021. This brought the price per share up to USD$7.46 early on in the trading day.

    Resounding Success of Q2 2021

    The second quarter of fiscal 2021 saw CYTH stock was marked by excellent execution across multiple fronts. The company recently reported positive topline results from its Phase 1/2 study in NPC, as well as positive long-term safety and efficacy from our Phase 1 open-label extension study. Accordingly, the company continued to build on the snowball event in the initiation of its pivotal Phase 3 study in NPC, as well as the commencement of commercial-scale manufacturing for Trappsol Cyclo. Furthermore, the company is moving forward with its strategy for its Alzheimer’s Disease program. This is on the basis of positive feedback from the United States Food and Drug Administration. The upcoming quarters are expected to hold a variety of catalytic milestones.

    CYTH Stock’s Trappsol Cyclo

    The company initiated the commercial-scale production of batches of Trappsol Cyclo over the course of the second quarter of fiscal 2021. Trappsol Cyclo will facilitate the support of the ongoing TransportNPC study in NPC1. NPC1 is the upcoming Phase 2 study in Alzheimer’s Disease. Trappsol Cyclo will also support CYTH stock’s active compassionate use program. The company also commenced site activation and patient enrollment for the TransportNPC study. The study is designed to evaluate Trappsol Cyclo for the treatment of NPC1.

    CYTH Stock’s Net Loss and R&D Costs

    Net loss for the second quarter of fiscal 2021 was reported at roughly USD$3.6 million. Research and development expenses were up by 54%, coming in at USD$2.6 million for Q2 2021. This is comparable to the USD$1.7 million for the three-month period ended June 30th, 2020. The year over year increase was largely driven by increased activity in CYTH stock’s international clinical program and U.S. clinical trials. The company forecasts R&D costs to further increase over the rest of 2021 as it continues to seek regulatory approval for the use of Trappsol Cyclo in the treatment of NPC and AD.

    Future Outlook for CYTH Stock

    The company reported strong financials for its second quarter of fiscal 2021. The company is keen to leverage the resources at its disposal to usher in organic growth over the long term. Current and potential investors are hopeful for sustained and significant increases in shareholder value.

  • Bridgeline Digital Inc. (BLIN) Stock Suffers Following Disclosure of Q3 202 Financial Reports

    Bridgeline Digital Inc. (BLIN) stock prices stayed stable over the course of the trading day on August 16th at USD$4.86. Subsequent current market fluctuations have seen the stock dip by 6.59%, bringing it down to USD$4.54.

    BLIN Stock’s Revenue Reports

    The third quarter of fiscal 2021 saw BLIN stock report total revenue in the amount of USD$3.4 million. Comprised of revenue from both Licenses and Services, total revenue was reported at USD$2.6 million for the quarter ended June 30th, 2020. Subscription and licenses revenue grew by 37% as compared to the prior-year quarter, while Services revenue was up by 15%.

    Gross Profit and Margin

    Gross profit was up 45% to USD$2.3 million for the third quarter of fiscal 2021, as compared to the USD$1.6 million reported in the prior-year quarter. Cost of revenue was also up, by 11%, to USD$1.2 million for Q3 2021, up from the USD$1.1 million reported in Q3 2020. Gross margin percentage increased to 65% for the quarter ended June 30th, 2021, as compared to the 59% reported in the prior-year quarter. Subscription and licenses gross margin percentage came in at 72% for the third quarter of fiscal 2021. This is comparable to the 64% reported for the third quarter of fiscal 2020.

    Operating Expense and Profit

    Operating expenses were up to USD$2.9 million for Q3 2021, up from the USD$1.4 million reported for the same time period of 2020. Quarterly totals as of June 30th, 2021 will include additional investment in sales and marketing. Acquisition-related expenses associated with the integration of Woorank and Hawksearch will also be included in the quarterly totals moving forward. Operating loss for the quarter ended June 30th, 2021 came in at USD$615,000, compared to an operating profit of USD$150,000 in Q3 2020.

    BLIN Stock Poised for Success

    BLIN stock reported a 31% topline growth over the third quarter of fiscal 2021. The company expects license and subscription revenue to grow by double digits in the last quarter of fiscal 2021.Q3 2021 saw the company win more license sales than ever before. BLIN has roughly USD$10 million in cash, providing a comfortable liquidity position that will accelerate its sales and marketing investments.

    Future Outlook for BLIN Stock

    The company reported a strong financial report for the third quarter of fiscal 2021. BLIN stock is keen to usher in organic growth over the long term with the execution of its business strategy. Investors are hopeful that this will translate into consistent gains in shareholder value.